Der Internist

, Volume 53, Issue 8, pp 924–933 | Cite as

Allergische Reaktionen der Lunge

  • A.R. Koczulla
  • B. Beutel
  • T. Greulich
  • A. Jerrentrup
  • C. Vogelmeier
Schwerpunkt
  • 359 Downloads

Zusammenfassung

Allergische Erkrankungen der Lunge können die Atemwege, das Lungenparenchym und die Gefäße der Lunge betreffen. Dazu gehören das exogen-allergische Asthma bronchiale, die exogen-allergische Alveolitis, die allergische bronchopulmonale Aspergillose und das Churg-Strauss-Syndrom. In Bezug auf die Art der allergischen Reaktion und deren pathophysiologische Konsequenzen unterscheiden sich die Krankheitsentitäten stark. Das therapeutische Vorgehen hängt von der vorliegenden Erkrankung ab. In diesem Zusammenhang werden Biologika, die spezifisch und kausal in die Erkrankung eingreifen, zukünftig möglicherweise eine größere Rolle spielen.

Schlüsselwörter

Hypersensibilität Asthma bronchiale Allergische bronchopulmonale Aspergillose Churg-Strauss-Syndrom Exogen-allergische Alveolitis 

Pulmonary allergic reactions

Abstract

Allergic diseases of the lungs may affect the airways, the pulmonary parenchyma and the pulmonary vessels. The most relevant representatives are allergic asthma, hypersensitivity pneumonitis, bronchopulmonary aspergillosis and the Churg-Strauss syndrome. The type of allergic reaction and the pathophysiological consequences vary considerably between these entities. New drugs target specific mechanisms based on new insights into the pathogenetic processes of the underlying disease.

Keywords

Hypersensitivity Bronchial asthma Aspergillosis, allergic bronchopulmonary Churg-Strauss syndrome Alveolitis, extrinsic allergic 

Literatur

  1. 1.
    Virchow JC (2010) Asthma—historical development, current status and perspectives. Pneumologie 64:541–549PubMedCrossRefGoogle Scholar
  2. 2.
    Ishizaka K, Ishizaka T (1976) Immunoglobulin E. Current status and clinical laboratory applications. Arch Pathol Lab Med 100:289–292PubMedGoogle Scholar
  3. 3.
    Ishizaka T, Ishizaka K, Tomioka H (1972) Release of histamine and slow reacting substance of anaphylaxis (SRS-A) by IgE-anti-IgE reactions on monkey mast cells. J Immunol 108:513–520Google Scholar
  4. 4.
    Evans DJ, Barnes PJ, Cluzel M, O’Connor BJ (1997) Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. Am J Respir Crit Care Med 156:11–16PubMedGoogle Scholar
  5. 5.
    Mosmann TR, Cherwinski H, Bond MW et al (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357Google Scholar
  6. 6.
    Galli SJ, Tsai M, Piliponsky AM (2008) The development of allergic inflammation. Nature 454:445–454PubMedCrossRefGoogle Scholar
  7. 7.
    Dvorak A (2005) Ultrastructural studies of human basophils and mast cells. J Histochem Cytochem 53:1043–1070Google Scholar
  8. 8.
    Galli SJ, Kalesnikoff J, Grimbaldeston MA et al (2005) Mast cells as „tunable“ effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23:749–786PubMedCrossRefGoogle Scholar
  9. 9.
    Bradding P, Walls AF, Holgate ST (2006) The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117:1277–1284Google Scholar
  10. 10.
    Marshall J (2004) Mast-cell responses to pathogens. Nat Rev Immunol 4:787–799PubMedCrossRefGoogle Scholar
  11. 11.
    Bradding P, Holgate ST (1996) The mast cell as a source of cytokines in asthma. Ann N Y Acad Sci 796:272–281CrossRefGoogle Scholar
  12. 12.
    Howarth PH, Bradding P, Quint D et al (1994) Cytokines and airway inflammation. Ann N Y Acad Sci 72:69–82CrossRefGoogle Scholar
  13. 13.
    Cevikbas F, Steinhoff A, Homey B, Steinhoff M (2007) Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy Clin Immunol 7:365–373PubMedCrossRefGoogle Scholar
  14. 14.
    Lalloo UG, Barnes PJ, Chung KF (1996) Pathophysiology and clinical presentations of cough. J Allergy Clin Immunol 98(5 Pt 2):91–96Google Scholar
  15. 15.
    Sarin S, Undem B, Sanico A, Togias A (2006) The role of the nervous system in rhinitis. J Allergy Clin Immunol 118:999–1016Google Scholar
  16. 16.
    Sampson HA, Muñoz-Furlong A, Bock SA et al (2005) Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 115:584–591Google Scholar
  17. 17.
    Kay A (2001) Allergy and allergic diseases. First of two parts. N Engl J Med 344:30–37Google Scholar
  18. 18.
    Kay A (2001) Allergy and allergic diseases. Second of two parts. N Engl J Med 344:109–113Google Scholar
  19. 19.
    Galli SJ, Grimbaldeston M, Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8:478–486PubMedCrossRefGoogle Scholar
  20. 20.
    Holgate ST (2007) Epithelium dysfunction in asthma. J Allergy Clin Immunol 120:1233–1244 (Quiz: 1245–1246)Google Scholar
  21. 21.
    Holgate ST (2007) The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol 28:248–251PubMedCrossRefGoogle Scholar
  22. 22.
    Knutsen AP, Bellone C, Kauffman H (2002) Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis. J Cyst Fibros 1:76–89Google Scholar
  23. 23.
    Reed CE (2007) Inflammatory effect of environmental proteases on airway mucosa. Curr Allergy Asthma Rep 7:368–374PubMedCrossRefGoogle Scholar
  24. 24.
    Knight DA, Lim S, Scaffidi AK et al (2001) Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J Allergy Clin Immunol 108:797–803Google Scholar
  25. 25.
    Pagnoux C, Guilpain P, Guillevin L (2007) Churg-Strauss syndrome. Curr Opin Rheumatol 19:25–32PubMedCrossRefGoogle Scholar
  26. 26.
    Dallos T, Heiland GR, Strehl J et al (2010) CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum 62:3496–3503PubMedCrossRefGoogle Scholar
  27. 27.
    Kiene M, Csernok E, Müller A et al (2001) Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 44:469–473PubMedCrossRefGoogle Scholar
  28. 28.
    Szczeklik W, Jakieła B, Adamek D, Musiał J (2011) Cutting edge issues in the Churg-Strauss syndrome. Clin Rev Allergy Immunol (im Druck)Google Scholar
  29. 29.
    Jakiela B, Sanak M, Szczeklik W et al (2011) Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 29(1 Suppl 64):23–34Google Scholar
  30. 30.
    Tsurikisawa N, Saito H, Tsuburai T et al (2008) Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 122:610–616Google Scholar
  31. 31.
    Bourke SJ, Dalphin JC, Boyd G et al (2001) Hypersensitivity pneumonitis: current concepts. Eur Respir J Suppl 32:81s–92sGoogle Scholar
  32. 32.
    Ando M, Suga M, Kohrogi H (1999) A new look at hypersensitivity pneumonitis. Curr Opin Pulm Med 5:299–304PubMedCrossRefGoogle Scholar
  33. 33.
    McFadden ER Jr, Lenner KA, Strohl KP (1986) Postexertional airway rewarming and thermally induced asthma. New insights into pathophysiology and possible pathogenesis. J Clin Invest 78:18–25Google Scholar
  34. 34.
    http://www.goldcopd.comGoogle Scholar
  35. 35.
    Global Initiative for Asthma. http://www.ginaasthma.orgGoogle Scholar
  36. 36.
    Abramson MJ, Puy RM, Weiner JM (2010) Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 8:CD001186PubMedGoogle Scholar
  37. 37.
    Jacobsen L, Niggemann B, Dreborg S et al (2007) Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62:943–948PubMedCrossRefGoogle Scholar
  38. 38.
    Thomson NC, Chaudhuri R, Spears M (2011) Emerging therapies for severe asthma. BMC Med 9:102PubMedCrossRefGoogle Scholar
  39. 39.
    Rodrigo GJ, Neffen H, Castro-Rodriguez JA (2011) Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139:28–35PubMedCrossRefGoogle Scholar
  40. 40.
    Leckie MJ (2003) Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2:245–259PubMedGoogle Scholar
  41. 41.
    Haldar P, Brightling CE, Hargadon B et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973–984Google Scholar
  42. 42.
    Pavord ID, Haldar P, Bradding P, Wardlaw AJ (2010) Mepolizumab in refractory eosinophilic asthma. Thorax 65:370PubMedCrossRefGoogle Scholar
  43. 43.
    Zarogiannis S, Gourgoulianis KI, Kostikas K (2009) Anti-interleukin-5 therapy and severe asthma. N Engl J Med 360:2576 (Autorenantwort: 2577)Google Scholar
  44. 44.
    Siegle JS, Hansbro N, Dong C et al (2011) Blocking induction of T helper type 2 responses prevents development of disease in a model of childhood asthma. Clin Exp Immunol 165:19–28PubMedCrossRefGoogle Scholar
  45. 45.
    Corren J, Lemanske RF, Hanania NA et al (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088–1098Google Scholar
  46. 46.
    Woodruff PG, Boushey HA, Dolganov GM et al (2007) Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 104:15858–15863CrossRefGoogle Scholar
  47. 47.
    Maes T, Joos GF, Brusselle GG (2012) Targeting interleukin-4 in asthma: lost in translation? Am J Respir Cell Mol Biol (im Druck)Google Scholar
  48. 48.
    Prenner BM, Bukofzer S, Behm S et al (2012) A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol (im Druck)Google Scholar
  49. 49.
    Hinson KFW, Moon AJ, Plummer NS (1952) Broncho-pulmonary aspergillosis. A review and a report of eight new cases. Thorax 7:317–333PubMedCrossRefGoogle Scholar
  50. 50.
    Greenberger PA (2002) Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 110:685–692Google Scholar
  51. 51.
    Knutsen AP, Bush RK, Demain JG et al (2012) Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 129:280–291 (Quiz: 292–293)Google Scholar
  52. 52.
    Greenberger PA (1988) Allergic bronchopulmonary aspergillosis and fungoses. Clin Chest Med 9:599–608PubMedGoogle Scholar
  53. 53.
    Crameri R, Hemmann S, Ismail C et al (1998) Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. Int Immunol 10:1211–1216PubMedCrossRefGoogle Scholar
  54. 54.
    Hartl D, Latzin P, Zissel G et al (2006) Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 173:1370–1376PubMedCrossRefGoogle Scholar
  55. 55.
    Hartl D, Buckland KF, Hogaboam CM (2006) Chemokines in allergic aspergillosis—from animal models to human lung diseases. Inflamm Allergy Drug Targets 5:219–228PubMedCrossRefGoogle Scholar
  56. 56.
    Rosenberg M, Patterson R, Roberts M, Wang J (1978) The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis. Am J Med 64:599–606PubMedCrossRefGoogle Scholar
  57. 57.
    Seaton A, Seaton RA, Wightman AJ (1994) Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids: a 15-year follow-up. QJM 87:529–537PubMedGoogle Scholar
  58. 58.
    Stevens DA, Schwartz HJ, Lee JY et al (2000) A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 342:756–762Google Scholar
  59. 59.
    Wark PA, Hensley MJ, Saltos N et al (2003) Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 111:952–957Google Scholar
  60. 60.
    Kanu A, Patel K (2008) Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 43:1249–1251PubMedCrossRefGoogle Scholar
  61. 61.
    Ent CK van der, Hoekstra H, Rijkers GT (2007) Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62:276–277PubMedCrossRefGoogle Scholar
  62. 62.
    Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL (2005) Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 53:93–99PubMedCrossRefGoogle Scholar
  63. 63.
    Harrold LR, Andrade SE, Go AS et al (2005) Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 32:1076–1080Google Scholar
  64. 64.
    Vaglio A, Martorana D, Maggiore U et al (2007) HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 56:3159–3166PubMedCrossRefGoogle Scholar
  65. 65.
    Guillevin L, Lhote F, Gayraud M et al (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75:17–28Google Scholar
  66. 66.
    Cohen P, Pagnoux C, Mahr A et al (2007) Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in 48 patients. Arthritis Rheum 57:686–693PubMedCrossRefGoogle Scholar
  67. 67.
    Zwerina J (2008) Churg-Strauss syndrome. Z Rheumatol 67:137–143 (Quiz: 144)Google Scholar
  68. 68.
    Ribi C, Cohen P, Pagnoux C et al (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58:586–594PubMedCrossRefGoogle Scholar
  69. 69.
    Koukoulaki M, Smith KG, Jayne DR (2006) Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65:557–559PubMedCrossRefGoogle Scholar
  70. 70.
    Cartin-Ceba R, Keogh KA, Specks U et al (2011) Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 26:2865–2871PubMedCrossRefGoogle Scholar
  71. 71.
    Rosenwasser LJ, Rothenberg ME (2010) IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J Allergy Clin Immunol 125:1245–1246Google Scholar
  72. 72.
    Sennekamp J, Joest M (2008) Recent advances in extrinsic allergic alveolitis. Pneumologie 62:51–54PubMedCrossRefGoogle Scholar
  73. 73.
    Sennekamp J, Müller-Wening D, Amthor M et al (2007) Guidelines for diagnosing extrinsic allergic alveolitis (hypersensitivity pneumonitis) (German Extrinsic Allergic Alveolitis Study Group). Pneumologie 61:52–56PubMedCrossRefGoogle Scholar
  74. 74.
    Hartman TE (2003) The HRCT features of extrinsic allergic alveolitis. Semin Respir Crit Care Med 24:419–426PubMedCrossRefGoogle Scholar
  75. 75.
    Lee TH, Wraith DG, Bennett CO, Bentley AP (1983) Budgerigar fancier’s lung. The persistence of budgerigar precipitins and the recovery of lung function after cessation of avian exposure. Clin Allergy 13:197–202PubMedCrossRefGoogle Scholar
  76. 76.
    Vogelmeier C, Mazur G, Pethran A et al (1995) Immunopathogenesis of extrinsic allergic alveolitis. Immun Infekt 23:86–91PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • A.R. Koczulla
    • 1
  • B. Beutel
    • 1
  • T. Greulich
    • 1
  • A. Jerrentrup
    • 1
  • C. Vogelmeier
    • 1
  1. 1.Klinik für Innere Medizin, Schwerpunkt PneumologiePhilipps-Universität MarburgMarburgDeutschland

Personalised recommendations